Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference



Rating:

Share or cite this content

Citations should be made in the following way:
M. Platé (London, United Kingdom). The promise of mTOR signaling as a therapeutic target for IPF. Virtual Congress 2020 – Reflections from the Lung Science 2020 conference

Member's Comments

No comment yet.

Related content which might interest you: The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021 Year: 2021 GCN2 regulates BMP signaling: consequence for PVOD pathobiology and therapeutic management Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 Targeting the mTOR signaling pathway to inhibit lung cell senescence in COPD Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro Year: 2020 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Wnt and TGF-beta signaling in lung development Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Nintedanib mediates effective modulation of relevant pro-fibrotic biomarkers ex vivo Source: International Congress 2019 – Pathogenesis and prognosis of interstitial lung disease of known origin Year: 2019